|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | G01N 33/68 | (2006.01) |
| G01N 33/50 | (2006.01) |
| (11) | Number of the document | 2653873 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13169139.6 |
| Date of filing the European patent application | 2008-02-07 | |
| (97) | Date of publication of the European application | 2013-10-23 |
| (45) | Date of publication and mention of the grant of the patent | 2022-07-20 |
| (46) | Date of publication of the claims translation | 2022-10-10 |
| (30) | Number | Date | Country code |
| 888921 P | 2007-02-08 | US |
| (72) |
Lukashev, Matvey, E. , US
O'Neill, Gilmore , US
|
| (73) |
Biogen MA Inc. ,
225 Binney Street, Cambridge, MA 02142,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti |
| Compositions and uses for treating Multiple Sclerosis |
| Payment date | Validity (years) | Amount | |
| 2026-01-21 | 19 | 347.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2025-11-26 |